Treatment of Acute Esophageal Variceal Bleeding in Liver Cirrhosis with High-Risk Criteria (Child–Pugh B/C or Elevated HVPG)

Acute variceal bleeding in a patient with liver cirrhosis is a time-critical emergency. When high-risk severity criteria are met, a specific, evidence-based treatment protocol determines the clinical approach.

Clinical Scenario

This protocol applies to patients with liver cirrhosis presenting with acute esophageal variceal bleeding who meet at least one of the following criteria: Child–Pugh class C (below 14 points), Child–Pugh class B (above 7 points) with active bleeding confirmed at initial endoscopy, or hepatic venous pressure gradient (HVPG) above 16 mmHg at the time of haemorrhage. These criteria identify patients at elevated risk for re-bleeding and mortality who require a defined management approach.

Treatment Approach (Partial)

First-line management combines a vasoactive drug, started urgently after the index bleed, with endoscopic therapy. Additional components of the protocol address infection prophylaxis and transfusion targets. The complete drug selection, sequence, timing requirements, and thresholds are contained in the full protocol.

Clinical Goals

The primary target is control of acute variceal bleeding, defined as cessation of bleeding with haemodynamic stability — systolic blood pressure above 90 mmHg and mean arterial pressure at least 60 mmHg — sustained for a minimum of 48 hours following therapy.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s12072-025-10894-4

Pre-emptive TIPS with PTFE covered stents within 72 h (ideally < 24 h) reduces re-bleeding and improves survival in carefully selected patients who met any of the following criteria: Child–Pugh class C < 14 points or Child–Pugh class B > 7 with active bleeding at initial endoscopy or HVPG > 16 mmHg at the time of hemorrhage.
Combination of a vasoactive drug and endoscopic therapy is the first-line therapy for acute variceal bleed.
Vasoactive treatment should be started at the earliest, preferably within 30 minutes of index bleed.
Band ligation with multi-band ligator is the preferred modality of therapy for esophageal variceal bleed.
For patients with cirrhosis with AVB, a broad-spectrum antibiotic like ceftriaxone (1-2 gram daily) is recommended for 5 days before endoscopic therapy.
Control of AVB is defined as the cessation of bleeding with hemodynamic stability (systolic blood pressure > 90 mmHg and MAP ≥ 60 mmHg) for at least 48 h post-therapy.

View source ↗